PET scan study to predict antidepressant response for depression
Part of Mental health clinical trials.
This study uses a special brain scan (PET scan) to see if it can predict how well people with depression will respond to a common type of antidepressant called an SSRI. The goal is to help doctors choose the right treatment earlier.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years old or older.
- You have been prescribed an SSRI antidepressant (like Prozac, Zoloft, or Lexapro) for depression.
- You are able to have a PET scan (a type of brain imaging).
- You do not have any other long-term brain or mental health conditions that started before the COVID-19 pandemic.
- You are covered by a health insurance plan in France.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study uses a special headband (TD-fNIRS) that measures brain activity to see if it can predict how well different depression treatments work. You would be starting a new treatment for depression (like ketamine, SPRAVATO, TMS, or antidepressants) and wear the headband before and during treatment.
This study uses brain scans to understand depression that starts soon after COVID-19. Researchers want to see if there are changes in brain chemistry related to depression, and you may help find new treatment targets.
This trial uses computer modeling based on brain measurements to try to predict which depression treatment will work for you. It may help match you with the most effective option faster by understanding your motivation-related brain patterns.
This study uses brain imaging (PET scans) to understand depression in people with Parkinson's disease. It may also test a depression treatment called ketamine, but the main goal is to see how the brain changes with depression.
This trial looks at how a specific brain receptor related to pain signals (nociceptin/orphanin FQ receptor) may be involved in depression. It may help researchers understand depression better by comparing people with current versus past (remitted) major depression.
This trial uses two special brain scans (DPA-714 and FDG PET/MRI) to look at inflammation and brain activity in people with first-episode or recurrent depression, and in healthy volunteers. It aims to find brain differences that could lead to better treatments.
Hear when a new Major Depressive Disorder trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.